POINT Biopharma Prices Public Offering of Common Stock
September 13, 2022 21:47 ET
|
POINT Biopharma
INDIANAPOLIS, Sept. 13, 2022 (GLOBE NEWSWIRE) -- POINT Biopharma Global Inc. (NASDAQ: PNT) (the “Company” or “POINT”), a company accelerating the discovery, development and global access to...
POINT Biopharma Provides Updated Efficacy and Safety Data from the Lead-In Cohort of the Phase 3 SPLASH Trial in mCRPC at ESMO Congress 2022
September 10, 2022 03:05 ET
|
POINT Biopharma
Newly published poster on the single-arm 27-patient safety and dosimetry lead-in provides key updates including: A median rPFS time of 11.5 months A best radiographic objective response (CR, PR)...
ITM to Present Trial Design of Ongoing Phase III COMPOSE Study in Advanced Neuroendocrine Tumors at ESMO 2022
September 06, 2022 05:00 ET
|
ITM Isotope Technologies Munich SE
Garching / Munich, September 6, 2022 – ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, today announced that a scientific poster on the design of its second...
POINT Biopharma Announces Poster Presentation at ESMO Congress 2022 Containing Efficacy & Safety Data from Lead-In Cohort of Phase 3 SPLASH Trial
September 04, 2022 18:10 ET
|
POINT Biopharma
INDIANAPOLIS, Sept. 04, 2022 (GLOBE NEWSWIRE) -- POINT Biopharma Global Inc. (NASDAQ: PNT) (the “Company” or “POINT”), a company accelerating the discovery, development, and global access to...
POINT Biopharma to Publish Abstract at ESMO Congress 2022 Containing Efficacy & Safety Data from Lead-In Cohort of Phase 3 SPLASH Trial
August 18, 2022 16:30 ET
|
POINT Biopharma
In advance of the abstract publication, POINT hosted an educational webinar entitled “Understanding the PNT2002 Phase 3 SPLASH Trial Control Arm” Watch the replay at...
POINT Biopharma Reports Second Quarter 2022 Financial Results and Provides Business Highlights
August 12, 2022 08:30 ET
|
POINT Biopharma
Additional data from the lead-in of PNT2002's SPLASH trial on track for fall 2022 release PNT6555, the lead of the pan-cancer PNT2004 fibroblast activation protein-alpha targeted program, enters...
POINT Biopharma to Host Investor Education Event, “Understanding the PNT2002 Phase 3 SPLASH Trial Control Arm”, on August 18, 2022
August 08, 2022 08:30 ET
|
POINT Biopharma
The event will prepare investors for the release of SPLASH’s lead-in cohort efficacy data later this year by providing an overview of SPLASH’s trial design. Register online today at...
ITM Signs Clinical Supply Agreement with Y-mAbs for n.c.a. Lutetium-177
July 21, 2022 05:21 ET
|
ITM Isotope Technologies Munich SE
ITM to supply its medical radioisotope, no-carrier-added Lutetium-177, for the clinical development of Y-mAbs’ Targeted Radionuclide Therapy candidate GD2-SADA: 177Lu-DOTA Complex for GD2-positive...
POINT Biopharma to Participate in Upcoming Investor Conferences
July 06, 2022 08:30 ET
|
POINT Biopharma
INDIANAPOLIS, July 06, 2022 (GLOBE NEWSWIRE) -- POINT Biopharma Global Inc. (NASDAQ: PNT) (the “Company” or “POINT”), a company accelerating the discovery, development and global access to...
ITM: New Isotope Production System at Bruce Power Successfully Produces First Medical Isotope
June 21, 2022 11:45 ET
|
ITM Isotope Technologies Munich SE
First-of-a-kind Isotope Production System continues to progress towards commercial, industrial-scale production of medical isotopes for cancer therapeutics ONTARIO, CANADA, and MUNICH, GERMANY – June...